All In Biotech

Drug Trial Radar · NCT05393063

A Study to Evaluate the Efficacy and Safety of AK127 in Patients With Advanced Solid Tumors

A Phase I Open-label Clinical Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of AK127 Monotherapy in Patients With Advanced Malignant Tumors

Last checked: Nov 19, 2026Latest source record: May 26, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

36

Planned (sponsor's estimate)

Start

Jun 2022

Primary completion

Jun 2023

Study completion Jun 2024

Sponsor

Lead sponsor
AkesoIndustry
Sponsor type
Industry
First posted
May 26, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is to characterize the safety, tolerability and anti-tumor activity of AK127 as a single agent in adult subjects with advanced solid tumor malignancies.

Conditions

  • Advanced Solid Tumors

Interventions

  • AK127Drug

    Subjects will receive AK127 by intravenous administration(administered on Day 1 of each cycle, Q3W)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with adverse events (AEs)Time frame: From the subject signs the ICF to 30 days (AE) and 90 days (SAE) after the last dose of study treatment or initiation of other anti-tumor therapy, whichever occurs first
  2. Number of participants with a Dose Limiting Toxicity (DLT)Time frame: During the first 21 days

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.